AR033425A1 - Uso de agonistas inversos de gabaa en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos - Google Patents

Uso de agonistas inversos de gabaa en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos

Info

Publication number
AR033425A1
AR033425A1 ARP020100693A ARP020100693A AR033425A1 AR 033425 A1 AR033425 A1 AR 033425A1 AR P020100693 A ARP020100693 A AR P020100693A AR P020100693 A ARP020100693 A AR P020100693A AR 033425 A1 AR033425 A1 AR 033425A1
Authority
AR
Argentina
Prior art keywords
strogens
vitamin
agonists
agonist
disease
Prior art date
Application number
ARP020100693A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR033425A1 publication Critical patent/AR033425A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Una composicion farmacéutica y un procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamífero que comprende la administracion de un agonista inverso de GABA(A), o una sal farmacéuticamente aceptable del mismo; y un agonista parcial del receptor de nicotina, un agente estrogénico, un modulador selectivo del receptor de estrogenos o vitamina E, o una sal farmacéuticamente aceptable de los mismos; y un vehículo farmacéuticamente aceptable. El agonista inverso de GABA(A) y el agonista parcial del receptor de nicotina, los estrogenos, el modulador selectivo de receptor de estrogeno o la vitamina E están presentes en cantidades que hacen que la composicion sea eficaz para potenciar la cognicion o en el tratamiento de enfermedades de disfuncion cognitiva, incluyendo, pero sin limitacion la enfermedad de Alzheimer (AD), deterioro cognitivo leve, reduccion cognitiva relacionada con la edad, demencia vascular, enfermedad de Parkinson, enfermedad de Huntington, pérdida de la memoria asociada con la depresion o la ansiedad, esquizofrenia, síndrome de Down, apoplejía, lesion cerebral traumática (TBI), demencia asociada con el SIDA y trastorno de déficit de atencion. También se describe el procedimiento para usar estas composiciones.
ARP020100693A 2001-03-01 2002-02-27 Uso de agonistas inversos de gabaa en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos AR033425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27256601P 2001-03-01 2001-03-01

Publications (1)

Publication Number Publication Date
AR033425A1 true AR033425A1 (es) 2003-12-17

Family

ID=23040351

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100693A AR033425A1 (es) 2001-03-01 2002-02-27 Uso de agonistas inversos de gabaa en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos

Country Status (33)

Country Link
US (2) US20020193360A1 (es)
EP (1) EP1363606A1 (es)
JP (1) JP2004527500A (es)
KR (1) KR20030076717A (es)
CN (1) CN1494422A (es)
AP (1) AP2002002465A0 (es)
AR (1) AR033425A1 (es)
BG (1) BG108131A (es)
BR (1) BR0207802A (es)
CA (1) CA2439581A1 (es)
CR (1) CR7059A (es)
CZ (1) CZ20032338A3 (es)
DO (1) DOP2002000345A (es)
EA (1) EA200300854A1 (es)
EC (1) ECSP034759A (es)
EE (1) EE200300422A (es)
GT (1) GT200200039A (es)
HU (1) HUP0303448A3 (es)
IL (1) IL157465A0 (es)
IS (1) IS6905A (es)
MA (1) MA26999A1 (es)
MX (1) MXPA03007834A (es)
NO (1) NO20033821L (es)
NZ (1) NZ527397A (es)
OA (1) OA12554A (es)
PA (1) PA8540701A1 (es)
PE (1) PE20020927A1 (es)
PL (1) PL364081A1 (es)
SK (1) SK10752003A3 (es)
TN (1) TNSN02018A1 (es)
UY (1) UY27188A1 (es)
WO (1) WO2002069948A1 (es)
ZA (1) ZA200306193B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
WO2005000806A2 (en) 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
EP2682481A3 (en) * 2005-08-03 2014-09-17 The Johns-Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
WO2007139818A2 (en) 2006-05-22 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
DK2074123T3 (da) * 2006-10-16 2013-01-14 Bionomics Ltd Nye anxiolytiske forbindelser
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
AU2013202426B2 (en) * 2006-10-16 2015-08-06 Bionomics Limited Novel anxiolytic compounds
EP3332797A3 (en) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US10206921B2 (en) * 2009-06-03 2019-02-19 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (CNS) injury
US8178537B2 (en) * 2009-06-22 2012-05-15 Teva Pharmaceutical Industries Ltd. Solid state forms of varenicline salts and processes for preparation thereof
MX346185B (es) 2010-11-15 2017-03-10 Agenebio Inc Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
US9023848B2 (en) 2011-03-02 2015-05-05 Bionomics Limited Small-molecules as therapeutics
US20140051701A1 (en) * 2011-03-02 2014-02-20 Bionomics Limited Methods of treating a disease or condition of the central nervous system
NZ615466A (en) 2011-05-12 2016-02-26 Bionomics Ltd Methods for preparing naphthyridines
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2016279052A1 (en) 2015-06-19 2018-02-15 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
CN116008442B (zh) * 2023-03-27 2023-06-30 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂的合成中间体的杂质检测方法
CN116077459B (zh) * 2023-04-10 2023-07-07 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂的胶囊剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514181A (ja) * 1997-08-25 2001-09-11 ニューロゲン コーポレイション Gaba脳レセプタリガンドとしての置換4−オキソ−ナフチリジン−3−カルボキサミド
WO2000071528A1 (en) * 1999-05-25 2000-11-30 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands

Also Published As

Publication number Publication date
US20020193360A1 (en) 2002-12-19
BR0207802A (pt) 2004-03-09
PA8540701A1 (es) 2002-09-30
US20040082555A1 (en) 2004-04-29
SK10752003A3 (sk) 2004-08-03
KR20030076717A (ko) 2003-09-26
NZ527397A (en) 2005-05-27
TNSN02018A1 (fr) 2005-12-23
CR7059A (es) 2004-03-10
IS6905A (is) 2003-08-07
AP2002002465A0 (en) 2002-06-30
MA26999A1 (fr) 2004-12-20
OA12554A (en) 2006-06-07
UY27188A1 (es) 2002-10-31
JP2004527500A (ja) 2004-09-09
GT200200039A (es) 2002-11-21
IL157465A0 (en) 2004-03-28
HUP0303448A3 (en) 2005-05-30
WO2002069948A1 (en) 2002-09-12
EA200300854A1 (ru) 2004-02-26
CZ20032338A3 (cs) 2004-08-18
PE20020927A1 (es) 2002-10-30
DOP2002000345A (es) 2002-12-15
CN1494422A (zh) 2004-05-05
ECSP034759A (es) 2003-10-28
ZA200306193B (en) 2004-08-11
EE200300422A (et) 2004-02-16
NO20033821L (no) 2003-09-10
HUP0303448A2 (hu) 2004-01-28
PL364081A1 (en) 2004-12-13
MXPA03007834A (es) 2003-12-08
BG108131A (en) 2004-09-30
EP1363606A1 (en) 2003-11-26
NO20033821D0 (no) 2003-08-28
CA2439581A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AR033425A1 (es) Uso de agonistas inversos de gabaa en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos
ECSP014065A (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero
ATE463247T1 (de) Bupropion metaboliten zur behandlung von angstzuständen
CO5261590A1 (es) Un derivado de pirrolidinacetamida solo o en combinacion para el tratamineto de transtornos del sistema nervioso central (cns)
BR9509807A (pt) Composição líquida para administração oral e processo para tratar um mamífero incluindo o homem que esteja sofrendo de um quadro clinico mediado pela aç o do 5ht nos receptores 5ht3
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
PA8493701A1 (es) Compuestos para tratar la obesidad
YU64600A (sh) Smeša supstanci za topikalnu primenu
UY27023A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip
IT1219667B (it) Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
AR047719A1 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri
DE69928521D1 (de) Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
SV2001000465A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos ref. pc10733/20144/bb
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
ATE6643T1 (de) Neue 3,4-diaza-bicyclo(4.1.0)hepten-(2)-one-(5), verfahren zu ihrer herstellung und diese verbindungen enthaltende therapeutische mittel.
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
AR032711A1 (es) Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
BR0107969A (pt) Uso de um composto, uso de um diastereoisÈmero na forma pura ou de uma mistura de diastereoisÈmeros do composto, composto, composição farmacêutica, método para o tratamento e profilaxia de osteoporose e condições ósseas relacionadas, e, método para o tratamento de pacientes sofrendo de condições patológicas
HUP9701606A2 (hu) Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
DE60129846D1 (de) Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems

Legal Events

Date Code Title Description
FA Abandonment or withdrawal